Anthracycline, Trastuzumab for Breast CA Up Heart Failure Risk

Risk of heart failure and/or cardiomyopathy up for women with incident, invasive breast cancer

WEDNESDAY, Sept. 5 (HealthDay News) -- For women with incident, invasive breast cancer, treatment with anthracycline and trastuzumab is associated with an increased risk of heart failure and/or cardiomyopathy, compared to having no chemotherapy, according to a study published in the Sept. 5 issue of the Journal of the National Cancer Institute.

To estimate the association between anthracycline and trastuzumab use and incident heart failure and/or cardiomyopathy, Erin J. Aiello Bowles, M.P.H., from the Group Health Research Institute in Seattle, and colleagues retrospectively analyzed data from a cohort of 12,500 women (mean age, 60 years) diagnosed with incident, invasive breast cancer from Jan. 1, 1999, to Dec. 31, 2007. Procedure and pharmacy codes were used to identify chemotherapy use.

The researchers found that 29.6 percent of participants received anthracycline alone, 0.9 percent received trastuzumab alone, 3.5 percent received both anthracycline and trastuzumab, 19.5 percent received other chemotherapy, and 46.5 percent received no chemotherapy. Compared with recipients of other chemotherapy or no chemotherapy, recipients of anthracycline and trastuzumab were younger, with fewer comorbidities. The risk of heart failure and/or cardiomyopathy was increased for patients treated with anthracycline alone (adjusted hazard ratio [aHR], 1.40), compared to no chemotherapy, and was similar to the risk seen for patients treated with other chemotherapy (aHR, 1.49). Patients treated with trastuzumab alone or anthracycline plus trastuzumab had a highly increased risk (aHR, 4.12 and 7.19, respectively).

"Anthracycline and trastuzumab were primarily used in younger, healthier women and associated with increased heart failure and/or cardiomyopathy risk compared with no chemotherapy," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text
Editorial

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Debunking Three Rape Myths
Journal of Forensic Nursing, October/December 2014
Expires: 12/31/2016 CE:2.5 $24.95


Drug updates and approvals: 2014 in review
The Nurse Practitioner, 13December 2014
Expires: 12/31/2016 CE:3 $27.95


Can Food Processing Enhance Cancer Protection?
Nutrition Today, September/October 2014
Expires: 10/31/2016 CE:2 $21.95


More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events